Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip. 

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

Private Company Edition: Lilly will open a third accelerator, this time in San Diego, and Fosun partnered with Treehill to help later-stage firms get over the finish line. Also, Flagship – after recent UK investments – signals its next fund will total $3bn. ArrivoBio and Alto Neuroscience raised $45m each.

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.